Annexon Inc (ANNX)

$5.11 -0.38 (-6.92%)
Market Cap 648.41M
Revenue (ttm) 0.00
Net Income (ttm) -138.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 10,013,101
Avg Vol 2,627,482
Day's Range N/A - N/A
Shares Out 119.63M
Stochastic %K 4%
Beta 1.15
Analysts Strong Sell
Price Target $14.71

Company Profile

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also devel...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 822 5500
Fax: 650 636 9773
Address:
1400 Sierra Point Parkway, Building C Suite 200, Brisbane, United States
Determinedstocks
Determinedstocks Mar. 20 at 7:37 PM
$ANNX Had to pick up a few more shares. Question - after a slight recovery on Monday, does the Middle East continue to drag down the entire market? Hard to imagine that this is the lowest we go given the chaos swirling around us...
0 · Reply
Quantumup
Quantumup Mar. 19 at 3:54 PM
Cantor reiterated $ANNX Overweight ISEE - $ALPMY BofA reit'd Buy; $8 after ANNX's Geographic Atrophy Investor Day where BofA said: Vonaprument's novel MoA could drive visual acuity benefit Here's what Cantor and BofA had to say: https://x.com/Quantumup1/status/2034658656029954490?s=20
1 · Reply
Thomas105
Thomas105 Mar. 19 at 10:58 AM
$ANNX
2 · Reply
Lightening_strikes
Lightening_strikes Mar. 18 at 9:00 PM
$ANNX good update today on GA. What’s holding this stock back?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 18 at 4:12 PM
$ANNX RSI: 51.72, MACD: 0.0324 Vol: 0.34, MA20: 5.43, MA50: 5.73 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Rickylinderman
Rickylinderman Mar. 17 at 3:25 PM
$ANNX beat the crowds now. Whew
1 · Reply
Thomas105
Thomas105 Mar. 17 at 10:17 AM
$ANNX Tomorrow💪🏻
1 · Reply
Thomas105
Thomas105 Mar. 16 at 8:34 AM
$ANNX Today earnings?
0 · Reply
Lightening_strikes
Lightening_strikes Mar. 15 at 2:38 PM
$ANNX insider buys again. 8k shares
0 · Reply
EthanVghn
EthanVghn Mar. 12 at 4:37 PM
$ANNX low float biotech look here and squeeze risk rises fast if this clears range
0 · Reply
Latest News on ANNX
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Mar 16, 2026, 4:05 PM EDT - 5 days ago

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 25 days ago

Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference

Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy

Feb 17, 2026, 8:00 AM EST - 4 weeks ago

Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy

Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases

Jan 24, 2026, 2:08 AM EST - 2 months ago

Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Jan 16, 2026, 5:05 PM EST - 2 months ago

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon, Inc. (ANNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 5:06 PM EST - 2 months ago

Annexon, Inc. (ANNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026

Jan 12, 2026, 7:00 AM EST - 2 months ago

Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026

Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome

Jan 8, 2026, 8:00 AM EST - 2 months ago

Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome

Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 4:05 PM EST - 2 months ago

Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Annexon: Maintaining "Buy" Rating On Second C1q Inhibitor Advancement For Geographic Atrophy

Nov 20, 2025, 5:23 PM EST - 4 months ago

Annexon: Maintaining "Buy" Rating On Second C1q Inhibitor Advancement For Geographic Atrophy

Annexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

Nov 14, 2025, 4:01 PM EST - 4 months ago

Annexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 12, 2025, 10:55 PM EST - 4 months ago

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Nov 12, 2025, 4:12 PM EST - 4 months ago

Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Nov 10, 2025, 4:05 PM EST - 4 months ago

Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon, Inc. (ANNX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 7, 2025, 9:58 PM EDT - 6 months ago

Annexon, Inc. (ANNX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Annexon, Inc. (ANNX) Presents at Cantor Global Healthcare Conference 2025 Transcript

Sep 5, 2025, 1:38 AM EDT - 7 months ago

Annexon, Inc. (ANNX) Presents at Cantor Global Healthcare Conference 2025 Transcript

Annexon Biosciences to Participate in Upcoming September Investor Conferences

Aug 27, 2025, 8:00 AM EDT - 7 months ago

Annexon Biosciences to Participate in Upcoming September Investor Conferences

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Aug 14, 2025, 4:05 PM EDT - 7 months ago

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

Aug 7, 2025, 4:30 PM EDT - 8 months ago

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Jul 24, 2025, 7:00 AM EDT - 8 months ago

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Annexon: Lead GBS Therapy Stokes Near-Term Potential

Jul 14, 2025, 12:47 PM EDT - 8 months ago

Annexon: Lead GBS Therapy Stokes Near-Term Potential

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

Jun 18, 2025, 4:05 PM EDT - 9 months ago

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 4:05 PM EDT - 10 months ago

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

May 19, 2025, 4:05 PM EDT - 10 months ago

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

May 12, 2025, 8:00 AM EDT - 11 months ago

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

May 9, 2025, 5:00 PM EDT - 11 months ago

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

May 7, 2025, 8:00 AM EDT - 11 months ago

Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck

Apr 15, 2025, 7:12 AM EDT - 1 year ago

Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

Apr 8, 2025, 4:05 PM EDT - 1 year ago

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

Apr 3, 2025, 6:18 PM EDT - 1 year ago

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

Mar 3, 2025, 8:00 AM EST - 1 year ago

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 4:05 PM EST - 1 year ago

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

Feb 13, 2025, 8:30 AM EST - 1 year ago

Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 8:00 AM EST - 1 year ago

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

Dec 16, 2024, 7:30 AM EST - 1 year ago

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

Nov 14, 2024, 8:00 AM EST - 1 year ago

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

Nov 13, 2024, 4:05 PM EST - 1 year ago

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

Oct 21, 2024, 8:00 PM EDT - 1 year ago

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX)

Oct 3, 2024, 1:20 AM EDT - 1 year ago

Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX)

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Aug 17, 2024, 9:28 AM EDT - 1 year ago

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

Jul 11, 2024, 6:09 PM EDT - 1 year ago

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Jun 25, 2024, 5:00 PM EDT - 1 year ago

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Annexon Announces Pricing of $125 Million Underwritten Public Offering

Jun 5, 2024, 11:04 PM EDT - 1 year ago

Annexon Announces Pricing of $125 Million Underwritten Public Offering

Annexon Announces Proposed Public Offering of Common Stock

Jun 4, 2024, 5:06 PM EDT - 1 year ago

Annexon Announces Proposed Public Offering of Common Stock

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Jun 4, 2024, 2:07 PM EDT - 1 year ago

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Annexon's neurological disorder drug meets main goal of late-stage study

Jun 4, 2024, 7:11 AM EDT - 1 year ago

Annexon's neurological disorder drug meets main goal of late-stage study

Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

Jun 3, 2024, 4:30 PM EDT - 1 year ago

Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

May 13, 2024, 8:00 AM EDT - 2 years ago

Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

Annexon Biosciences to Present at the Bank of America Health Care Conference

May 9, 2024, 8:00 AM EDT - 2 years ago

Annexon Biosciences to Present at the Bank of America Health Care Conference

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

May 7, 2024, 12:30 PM EDT - 2 years ago

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

Determinedstocks
Determinedstocks Mar. 20 at 7:37 PM
$ANNX Had to pick up a few more shares. Question - after a slight recovery on Monday, does the Middle East continue to drag down the entire market? Hard to imagine that this is the lowest we go given the chaos swirling around us...
0 · Reply
Quantumup
Quantumup Mar. 19 at 3:54 PM
Cantor reiterated $ANNX Overweight ISEE - $ALPMY BofA reit'd Buy; $8 after ANNX's Geographic Atrophy Investor Day where BofA said: Vonaprument's novel MoA could drive visual acuity benefit Here's what Cantor and BofA had to say: https://x.com/Quantumup1/status/2034658656029954490?s=20
1 · Reply
Thomas105
Thomas105 Mar. 19 at 10:58 AM
$ANNX
2 · Reply
Lightening_strikes
Lightening_strikes Mar. 18 at 9:00 PM
$ANNX good update today on GA. What’s holding this stock back?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 18 at 4:12 PM
$ANNX RSI: 51.72, MACD: 0.0324 Vol: 0.34, MA20: 5.43, MA50: 5.73 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Rickylinderman
Rickylinderman Mar. 17 at 3:25 PM
$ANNX beat the crowds now. Whew
1 · Reply
Thomas105
Thomas105 Mar. 17 at 10:17 AM
$ANNX Tomorrow💪🏻
1 · Reply
Thomas105
Thomas105 Mar. 16 at 8:34 AM
$ANNX Today earnings?
0 · Reply
Lightening_strikes
Lightening_strikes Mar. 15 at 2:38 PM
$ANNX insider buys again. 8k shares
0 · Reply
EthanVghn
EthanVghn Mar. 12 at 4:37 PM
$ANNX low float biotech look here and squeeze risk rises fast if this clears range
0 · Reply
Ramanda87
Ramanda87 Mar. 12 at 3:51 PM
$ANNX what’s with the sudden drop?
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Mar. 12 at 1:52 PM
$ANNX somethings not good here
1 · Reply
Lightening_strikes
Lightening_strikes Mar. 12 at 1:36 PM
$ANNX very volatile in a tight range Let’s get to double digits already
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Mar. 11 at 11:01 PM
$ANNX news soon!?!
1 · Reply
makingdoughfromoptions
makingdoughfromoptions Mar. 11 at 10:33 AM
$ANNX Look at the long view here. If both drugs get approved, and I think they will, this is a $25 to $75 stock. And will be of interest to big pharma. Current SP a steal given pipeline status. 10k shares in here.
2 · Reply
Stockwatcher9999
Stockwatcher9999 Mar. 10 at 5:11 PM
$ANNX This company is loaded with blockbuster wide indication pipeline drugs. Very bright outlook
0 · Reply
Determinedstocks
Determinedstocks Mar. 10 at 4:41 PM
$ANNX Over $6 again. Will we finally start to rise like we should? Have investors started to discover this success story in the making?
0 · Reply
makingdoughfromoptions
makingdoughfromoptions Mar. 6 at 6:11 PM
$ANNX No reason other than market movement for SP to take a beating. Of course it tripled in short time so a step back is not surprising. The GBS approval @ EMA is a good 90% certainty. I expect replication of GA phase 3 results as compared to P2 results and that will be the golden egg.
2 · Reply
BANZAI79
BANZAI79 Mar. 5 at 3:12 PM
$ANNX for those who saw insiders selling, it was like a 1%-sell of their pos. Still waiting the fda approval very soon!
3 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 4 at 4:27 AM
$ANNX RSI: 45.54, MACD: -0.1069 Vol: 0.42, MA20: 5.37, MA50: 5.60 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BooEmmy
BooEmmy Mar. 3 at 3:03 PM
$ANNX if the market was up today this stock would be over 6, What a bummer
1 · Reply
Thomas105
Thomas105 Mar. 3 at 6:41 AM
$ANNX Today
1 · Reply